6127.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 13:38):

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally...

Stats
आज की मात्रा	2.26M
औसत मात्रा	1.63M
बाजार मूल्य	13.84B
EPS	HKD0.270 ( 2024-01-10 )
अगली कमाई की तारीख	( HKD0.0300 ) 2024-06-07
Last Dividend	HKD0.440 ( 2023-06-20 )
Next Dividend	HKD0 ( N/A )
P/E	-108.56
ATR14	HKD0.0100 (0.10%)

मात्रा सहसंबंध

लंबा: -0.21 (neutral)

छोटा: -0.84 (strong negative)

Signal:(50.109) Neutral

Joinn Laboratories सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Joinn Laboratories सहसंबंध - मुद्रा/वस्त्र

0.25
( neutral )

0.10
( neutral )

0.00
( neutral )

-0.21
( neutral )

-0.22
( neutral )

-0.49
( neutral )

Joinn Laboratories वित्तीय

Annual	2023
राजस्व:	HKD2.38B
सकल लाभ:	HKD1.01B (42.62 %)
EPS:	HKD0.530

FY	2023
राजस्व:	HKD2.38B
सकल लाभ:	HKD1.01B (42.62 %)
EPS:	HKD0.530

FY	2022
राजस्व:	HKD2.27B
सकल लाभ:	HKD1.09B (47.90 %)
EPS:	HKD2.01

FY	2021
राजस्व:	HKD1.52B
सकल लाभ:	HKD739.12M (48.73 %)
EPS:	HKD1.255

Financial Reports:

No articles found.

Joinn Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.420 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.440 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Joinn Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.95 - low (64.35%) | Divividend Growth Potential Score: 0.747 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.214	2021-06-23
Last Dividend	HKD0.440	2023-06-20
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD1.074	--
Avg. Dividend % Per Year	0.00%	--
Score	1.38	--
Div. Sustainability Score	4.95
Div.Growth Potential Score	0.747
Div. Directional Score	2.85	--

Next Divdend (Est)
(2025-05-12)

HKD0.460 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.38

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6939.HK	Ex Dividend Knight	2023-06-14	Annually	0.00%
1982.HK	Ex Dividend Junior	2023-07-06	Annually	0.00%
1050.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
0114.HK	Ex Dividend Knight	2023-10-03	Annually	0.00%
3600.HK	Ex Dividend Knight	2023-09-12	Annually	0.00%
1598.HK	Ex Dividend Junior	2023-07-13	Annually	0.00%
0635.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
9979.HK	Ex Dividend Knight	2023-07-11	Semi-Annually	0.00%
2182.HK	Ex Dividend Junior	2023-06-12	Annually	0.00%
1181.HK	Ex Dividend Knight	2023-09-13	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0270	1.500	-0.540	-0.810	[0 - 0.5]
returnOnAssetsTTM	-0.00647	1.200	-0.216	-0.259	[0 - 0.3]
returnOnEquityTTM	-0.00775	1.500	-1.197	-1.796	[0.1 - 1]
payoutRatioTTM	-3.40	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	4.64	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.40	0.800	0.602	0.482	[0.8 - 2.5]
cashRatioTTM	1.907	1.500	0.517	0.775	[0.2 - 2]
debtRatioTTM	0.00652	-1.500	9.89	-10.00	[0 - 0.6]
interestCoverageTTM	2.46	1.000	-0.198	-0.198	[3 - 30]
operatingCashFlowPerShareTTM	1.000	2.00	9.67	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.741	2.00	9.63	10.00	[0 - 20]
debtEquityRatioTTM	0.00794	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.398	1.000	6.70	6.70	[0.2 - 0.8]
operatingProfitMarginTTM	-0.000121	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	11.91	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.240	0.800	-1.736	-1.389	[0.5 - 2]
Total Score				4.95

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-107.45	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.00775	2.50	-0.770	-1.796	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.741	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	5.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.000	2.00	9.67	10.00	[0 - 30]
payoutRatioTTM	-3.40	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.324	1.000	4.39	0	[0.1 - 0.5]
Total Score				0.747

Joinn Laboratories

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.